{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T23:52:13Z","timestamp":1774569133119,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Antibiot"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1038\/s41429-026-00896-1","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T09:28:55Z","timestamp":1771320535000},"page":"264-273","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Meropenem, Ceftazidime, and Polymyxin B combination therapy: a novel approach to combat antimicrobial resistance in MDR, XDR and PDR Escherichia coli"],"prefix":"10.1038","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3502-7700","authenticated-orcid":false,"given":"Siddhi A.","family":"Darji","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Avani","family":"Raulji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4727-8114","authenticated-orcid":false,"given":"Axita","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Himanshu","family":"Pandya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4809-5494","authenticated-orcid":false,"given":"Rupal","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chirag","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9276-2023","authenticated-orcid":false,"given":"Bhaskar","family":"Datta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4287-2398","authenticated-orcid":false,"given":"Devjani","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,17]]},"reference":[{"key":"896_CR1","unstructured":"WHO Bacterial Priority Pathogens List, 2024. Bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance. Available from:https:\/\/www.who.int\/publications\/i\/item\/9789240093461Licence: CC BY-NC-SA 3.0 IGO, Accessed 25 May 2024."},{"key":"896_CR2","unstructured":"Sharma, Anuj. Indian Priority Pathogen List, 2021. To guide research, discovery and development of new antibiotics in India. https:\/\/dbtindia.gov.in\/sites\/default\/files\/IPPL_final.pdf, Accessed 25 May 2024."},{"key":"896_CR3","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","volume":"18","author":"AP Magiorakos","year":"2012","unstructured":"Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist BJ, Paterson DL. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18:268\u201381.","journal-title":"Clin Microbiol Infect"},{"key":"896_CR4","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1128\/AAC.01076-18","volume":"62","author":"K Bush","year":"2018","unstructured":"Bush K. Past and present perspectives on \u03b2-lactamases. Antimicrob Agents Chemother. 2018;62:10\u2013128.","journal-title":"Antimicrob Agents Chemother"},{"key":"896_CR5","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.3389\/fmicb.2019.01556","volume":"10","author":"R Domalaon","year":"2019","unstructured":"Domalaon R, Ammeter D, Brizuela M, Gorityala BK, Zhanel GG, Schweizer F. Repurposed antimicrobial combination therapy: Tobramycin-ciprofloxacin hybrid augments activity of the anticancer drug mitomycin C against multidrug-resistant Gram-negative bacteria. Front Microbiol. 2019;10:1556.","journal-title":"Front Microbiol"},{"key":"896_CR6","doi-asserted-by":"publisher","DOI":"10.1093\/femsle\/fnx142","volume":"364","author":"Y Feng","year":"2017","unstructured":"Feng Y, Bakker RT, van Hest RM, Hodiamont CJ, Brul S, Schultsz C, Ter Kuile BH. Optimization of therapy against Pseudomonas aeruginosa with ceftazidime and meropenem using chemostats as model for infections. FEMS Microbiol Lett. 2017;364:fnx142.","journal-title":"FEMS Microbiol Lett"},{"key":"896_CR7","first-page":"1","volume":"6","author":"FS Codjoe","year":"2017","unstructured":"Codjoe FS, Donkor ES. Carbapenem resistance: a review. Med Sci. 2017;6:1.","journal-title":"Med Sci"},{"key":"896_CR8","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1099\/jmm.0.063727-0","volume":"63","author":"MM Tav\u00edo","year":"2014","unstructured":"Tav\u00edo MM, Aquili VD, Vila J, Poveda JB. Resistance to ceftazidime in Escherichia coli associated with AcrR, MarR and PBP3 mutations and overexpression of sdiA. J Med Microbiol. 2014;63:56\u201365.","journal-title":"J Med Microbiol"},{"key":"896_CR9","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s40265-013-0013-7","volume":"73","author":"GG Zhanel","year":"2013","unstructured":"Zhanel GG, Lawson CD, Adam H, Schweizer F, Zelenitsky S, Lagac\u00e9-Wiens PR, Denisuik A, Rubinstein E, Gin AS, Hoban DJ, Lynch JP 3rd. Ceftazidime-avibactam: a novel cephalosporin\/\u03b2-lactamase inhibitor combination. Drugs. 2013;73:159\u201377.","journal-title":"Drugs"},{"key":"896_CR10","doi-asserted-by":"publisher","first-page":"e0285856","DOI":"10.1371\/journal.pone.0285856","volume":"18","author":"KA Ramsay","year":"2023","unstructured":"Ramsay KA, Rehman A, Wardell ST, Martin LW, Bell SC, Patrick WM, Winstanley C, Lamont IL. Ceftazidime resistance in Pseudomonas aeruginosa is multigenic and complex. PloS ONE. 2023;18:e0285856.","journal-title":"PloS ONE"},{"key":"896_CR11","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1016\/j.chembiol.2011.09.017","volume":"18","author":"M Shaheen","year":"2011","unstructured":"Shaheen M, Li J, Ross AC, Vederas JC, Jensen SE. Paenibacillus polymyxa PKB1 produces variants of polymyxin B-type antibiotics. Chem Biol. 2011;18:1640\u20138.","journal-title":"Chem Biol"},{"key":"896_CR12","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.eng.2020.11.005","volume":"13","author":"Y Wang","year":"2022","unstructured":"Wang Y, Luo Q, Xiao T, Zhu Y, Xiao Y. Impact of polymyxin resistance on virulence and fitness among clinically important gram-negative bacteria. Engineering. 2022;13:178\u201385.","journal-title":"Engineering"},{"key":"896_CR13","doi-asserted-by":"publisher","first-page":"643","DOI":"10.3389\/fmicb.2014.00643","volume":"5","author":"AO Olaitan","year":"2014","unstructured":"Olaitan AO, Morand S, Rolain JM. Mechanisms of polymyxin resistance: acquired and intrinsic resistance in bacteria. Front Microbiol. 2014;5:643.","journal-title":"Front Microbiol"},{"key":"896_CR14","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.drup.2010.05.002","volume":"13","author":"ME Falagas","year":"2010","unstructured":"Falagas ME, Rafailidis PI, Matthaiou DK. Resistance to polymyxins: mechanisms, frequency and treatment options. Drug Resist Updates. 2010;13:132\u20138.","journal-title":"Drug Resist Updates"},{"key":"896_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.sbi.2023.102647","volume":"82","author":"IC Materon","year":"2023","unstructured":"Materon IC, Palzkill T. Structural biology of MCR-1-mediated resistance to polymyxin antibiotics. Curr Opin Struct Biol. 2023;82:102647.","journal-title":"Curr Opin Struct Biol"},{"key":"896_CR16","doi-asserted-by":"crossref","unstructured":"Schuetz AN, Ferrell A, Hindler JA, Humphries R, Bobenchik AM. Overview of changes in the clinical and laboratory standards institute performance standards for antimicrobial susceptibility testing: M100 32nd and 33rd editions. J Clin Microbiol. 2025;63:e01623-23.","DOI":"10.1128\/jcm.01623-23"},{"key":"896_CR17","doi-asserted-by":"crossref","unstructured":"Sharma R, Patel S, Abboud C, Diep J, Ly NS, Pogue JM, Kaye KS, Li J, Rao GG. Polymyxin B in combination with meropenem against carbapenemase-producing Klebsiella pneumoniae: pharmacodynamics and morphological changes. Int J Antimicrob Agents. 2017;49:224\u201332.","DOI":"10.1016\/j.ijantimicag.2016.10.025"},{"key":"896_CR18","doi-asserted-by":"publisher","first-page":"204ra132","DOI":"10.1126\/scitranslmed.3006609","volume":"5","author":"L Imamovic","year":"2013","unstructured":"Imamovic L, Sommer MO. Use of collateral sensitivity networks to design drug cycling protocols that avoid resistance development. Sci Transl Med. 2013;5:204ra132.","journal-title":"Sci Transl Med"},{"key":"896_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/mdr.2023.0057","volume":"30","author":"P Khound","year":"2024","unstructured":"Khound P, Pandya H, Patel R, Patel N, Darji SA, Trivedi P, Mehta V, Raulji A, Banerjee D. An Approach to Track and analyze the trend of antimicrobial resistance using python: a pilot study for Anand, Gujarat, India\u2014May 2022\u2013August 2023. Microb Drug Resist. 2024;30:1\u201320.","journal-title":"Microb Drug Resist"},{"key":"896_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s12859-024-06005-z","volume":"26","author":"T Saratto","year":"2025","unstructured":"Saratto T, Visuri K, Lehtinen J, Ortega-Sanz I, Steenwyk JL, Sihvonen S. Solu: a cloud platform for real-time genomic pathogen surveillance. BMC Bioinform. 2025;26:12.","journal-title":"BMC Bioinform"},{"key":"896_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2024.1291876","volume":"15","author":"Y Han","year":"2024","unstructured":"Han Y, Zhang Y, Zhang X, Huang Z, Kong J, Wang X, Chen L, Wang Y, Cao J, Zhou T, Shen M. PAM-1: an antimicrobial peptide with promise against ceftazidime-avibactam resistant Escherichia coli infection. Front Microbiol. 2024;15:1291876.","journal-title":"Front Microbiol"},{"key":"896_CR22","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1128\/AAC.00271-19","volume":"63","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Wang X, Li X, Dong L, Hu X, Nie T, Lu Y, Lu X, Pang J, Li G, Yang X. Synergistic effect of colistin combined with PFK-158 against colistin-resistant Enterobacteriaceae. Antimicrob Agents Chemother. 2019;63:10\u2013128.","journal-title":"Antimicrob Agents Chemother"},{"key":"896_CR23","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1093\/cid\/ciy378","volume":"67","author":"SS Kadri","year":"2018","unstructured":"Kadri SS, Adjemian J, Lai YL, Spaulding AB, Ricotta E, Prevots DR, Palmore TN, Rhee C, Klompas M, Dekker JP, Powers IIIJH. Difficult-to-treat resistance in gram-negative bacteremia at 173 US hospitals: retrospective cohort analysis of prevalence, predictors, and outcome of resistance to all first-line agents. Clin Infect Dis. 2018;67:1803\u201314.","journal-title":"Clin Infect Dis"},{"key":"896_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s12941-024-00720-4","volume":"23","author":"Y Wang","year":"2024","unstructured":"Wang Y, Feng J, Yu J, Wen L, Chen L, An H, Xiao W, Zhang B, Feng H, Zhou M, Jiang Z. Potent synergy and sustained bactericidal activity of polymyxins combined with Gram-positive only class of antibiotics versus four Gram-negative bacteria. Ann Clin Microbiol Antimicrob. 2024;23:60.","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"896_CR25","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/j.cmi.2020.03.035","volume":"26","author":"A Nutman","year":"2020","unstructured":"Nutman A, Lellouche J, Temkin E, Daikos G, Skiada A, Durante-Mangoni E, Dishon-Benattar Y, Bitterman R, Yahav D, Daitch V, Bernardo M. Colistin plus meropenem for carbapenem-resistant Gram-negative infections: In vitro synergism is not associated with better clinical outcomes. Clin Microbiol Infect. 2020;26:1185\u201391.","journal-title":"Clin Microbiol Infect"},{"key":"896_CR26","doi-asserted-by":"publisher","first-page":"520","DOI":"10.4103\/ijmr.IJMR_760_19","volume":"154","author":"A Goel","year":"2021","unstructured":"Goel A, Gupta V, Singhal L, Palta S, Chander J. In vitro evaluation of antibiotic synergy for carbapenem-resistant Klebsiella pneumoniae clinical isolates. Indian J Med Res. 2021;154:520\u20136.","journal-title":"Indian J Med Res"},{"key":"896_CR27","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.ijmmb.2020.10.018","volume":"39","author":"S Dhandapani","year":"2021","unstructured":"Dhandapani S, Sistla S, Gunalan A, Manoharan M, Sugumar M, Sastry AS. In-vitro synergistic activity of colistin and meropenem against clinical isolates of carbapenem resistant E. coli and Klebsiella pneumoniae by checkerboard method. Indian J Med Microbiol. 2021;39:6\u201310.","journal-title":"Indian J Med Microbiol"},{"key":"896_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2020.533209","volume":"11","author":"C Zhou","year":"2020","unstructured":"Zhou C, Wang Q, Jin L, Wang R, Yin Y, Sun S, Zhang J, Wang H. In vitro synergistic activity of antimicrobial combinations against blaKPC and blaNDM-Producing Enterobacterales with blaIMP or mcr genes. Front Microbiol. 2020;11:533209.","journal-title":"Front Microbiol"},{"key":"896_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2022.1024702","volume":"13","author":"J Zhang","year":"2022","unstructured":"Zhang J, Diao S, Liu Y, Wang H, Liu Y, Zhu S, Feng K, Tang X, Oo C, Zhu P, Lv Z. The combination effect of meropenem\/sulbactam\/polymyxin Bon the pharmacodynamic parameters for mutant selection windows against carbapenem-resistant Acinetobacter baumannii. Front Microbiol. 2022;13:1024702.","journal-title":"Front Microbiol"},{"key":"896_CR30","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/j.1469-0691.1999.tb00095.x","volume":"5","author":"AP MacGowan","year":"1999","unstructured":"MacGowan AP, Rynn C, Wootton M, Bowker KE, Holt HA, Reeves DS. In vitro assessment of colistin\u2019s antipseudomonal antimicrobial interactions with other antibiotics. Clin Microbiol Infect. 1999;5:32\u20136.","journal-title":"Clin Microbiol Infect"}],"container-title":["The Journal of Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41429-026-00896-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41429-026-00896-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41429-026-00896-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T23:02:18Z","timestamp":1774566138000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41429-026-00896-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,17]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["896"],"URL":"https:\/\/doi.org\/10.1038\/s41429-026-00896-1","relation":{},"ISSN":["0021-8820","1881-1469"],"issn-type":[{"value":"0021-8820","type":"print"},{"value":"1881-1469","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,17]]},"assertion":[{"value":"11 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}